From Clinical Inertia to Precision Prevention

NEW DELHI / NEW YORK — At the 8th Eternal Heart Conclave (EHC) – 2026, one of the premier global summits in cardiovascular medicine, Dr. Jeffrey I. Mechanick, MD, Medical Director of the Kravis Center for Cardiovascular Health at Mount Sinai Fuster Heart Hospital and Senior Investigator with the METRICS Consortium, delivered a landmark keynote address on the urgent imperative to transform preventive cardiometabolic care: «Operationalizing the Cardiometabolic-Based Chronic Disease (CMBCD) Model in Preventive Care».

The Global Paradox and the Failure of Fragmented Care Models

Opening his address, Dr. Mechanick delineated the central paradox confronting contemporary healthcare: despite cardiovascular disease (CVD) remaining the leading cause of mortality worldwide, clinical practice remains trapped in pervasive clinical inertia, perpetually managing late-stage organ damage rather than preempting disease upstream.

The epidemiologic realities highlighted during the lecture underscore the systemic scale of this challenge: among United States adults, the prevalence of at least one chronic condition has reached 76.4% (surging to 93% in adults aged 65 and older). Most critically, the 12% of the population living with five or more chronic conditions accounts for 90% of total healthcare expenditures, imposing an unsustainable economic burden that disproportionately impacts socioeconomically disadvantaged communities.

«The traditional paradigm of treating isolated organ silos—managing hypertension in one clinic, diabetes in another, and dyslipidemia as a separate biochemical anomaly—has demonstrably failed to alter long-term population trajectories,» emphasized Dr. Mechanick. «We require an integrated pathophysiological paradigm that directly links upstream exposures to biological responses and enables actionable, stage-matched clinical intervention.»

The Four-Step Operational Loop: Identify, Stage, Intervene, and Reassess

The core of the presentation articulated the pragmatic operationalization of the CMBCD model developed by the METRICS Consortium. This framework translates complex biological networks into a clear four-step clinical decision loop:

  1. IDENTIFY: Comprehensive phenotyping of primary drivers (genomics, exposome, social determinants, and lifestyle behaviors) and secondary drivers (abnormal adiposity, dysglycemia, hypertension, and atherogenic dyslipidemia) to isolate the Dominant Driver governing the individual’s cardiometabolic trajectory.
  2. STAGE: Patient stratification across a harmonized four-stage progressive continuum: Stage 1 (Risk), Stage 2 (Predisease), Stage 3 (Manifest Clinical Disease), and Stage 4 (Target-Organ Complications), tracking specific endpoints including atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and atrial fibrillation (AF).
  3. INTERVENE: Prioritized therapeutic targeting of the dominant driver through stage-matched modalities, pairing intensive lifestyle medicine with potent pharmacotherapies (GLP-1 receptor agonists, dual/triple incretin mimetics, and SGLT2 inhibitors).
  4. REASSESS: Continuous, longitudinal reassessment of driver activity, phenotypic evolution, therapeutic responsiveness, and residual cardiometabolic risk to eliminate clinical inertia.

Emerging Technologies and Strategic Priorities

Dr. Mechanick identified three critical areas required to scale the operationalized CMBCD model across health systems:

  • Opportunistic AI Phenotyping: Deploying artificial intelligence algorithms to opportunistically quantify ectopic fat depots (pericardial, epicardial, and hepatic adiposity) from routine, existing clinical imaging.
  • Network-Based Classifiers: Translating biological network strain and entropy-based scoring into real-time electronic health record decision support.
  • Comprehensive Lifestyle Medicine Centers: Establishing multidisciplinary clinical infrastructures where preventive cardiology, metabolic endocrinology, clinical nutrition, and digital health converge seamlessly.

The METRICS Consortium continues to advance translational research and epidemiological modeling, establishing the driver-based chronic disease architecture as the international benchmark to eliminate clinical inertia and achieve sustainable cardiometabolic health.